Patience, all. The relevant context is that average time from the first clinical trial to approval for sale is about eight years, give or take. Orphan drug status was a great accelerator in our case, and of course most here hope that a cash-out point will be reached somewhere along the line without having to stay the whole course. But if you are in this to get your golden egg tomorrow, look elsewhere. As to management, if there's nothing to report, there's little point in reporting it! That doesn't make them poor managers.
- Forums
- ASX - By Stock
- Ann: Patrys - Details of PAT-SM6 & Carfilzomib Clinical Trial
Patience, all. The relevant context is that average time from...
Featured News
Add PAB (ASX) to my watchlist
|
|||||
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M |
Open | High | Low | Value | Volume |
0.6¢ | 0.7¢ | 0.6¢ | $820 | 120K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 1134114 | 0.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.7¢ | 1366308 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 1134114 | 0.006 |
14 | 7550157 | 0.005 |
10 | 5864000 | 0.004 |
6 | 6065682 | 0.003 |
2 | 2770000 | 0.002 |
Price($) | Vol. | No. |
---|---|---|
0.007 | 1000160 | 2 |
0.008 | 2061233 | 5 |
0.009 | 431000 | 1 |
0.010 | 1396000 | 6 |
0.011 | 680000 | 2 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online